Quarterly RNA drug plozasiran turns off a liver gene, sharply lowering life‑threatening pancreatitis attacks in a rare ...
Nanomedicine prompts RNA to make protein-based drugs to treat diseases. Now we can fine-tune protein production by dialling ...
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s ...
Vivatides Therapeutics raises $54M to advance RNA therapies beyond the liver, targeting new disease areas and accelerating ...
A research team from The Hong Kong University of Science and Technology (HKUST) has made a breakthrough discovery in understanding the molecular machinery of RNA silencing. The team uncovered how the ...
CHAPEL HILL, North Carolina — University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a “two-in-one” molecule that can simultaneously turn off two notoriously ...
Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...
University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a "two-in-one" molecule that can simultaneously turn off two notoriously difficult-to-target ...
Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...
Years of experiments and databases filled with RNA-seq results belie the simple reality that, until fairly recently, it was impossible to analyze RNA directly. The RNA-seq studies performed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results